Association between clinical use of lansoprazole and the risk of type 2 diabetes mellitus: A pharmacoepidemiological cohort study

Author:

Lin Ming-Hsun1,Wu Wen‐Tung1,Chen Yong-Chen2,Lin Tsung-Kun3,Chou Yu‐Ching2,Sun Chien-An2

Affiliation:

1. Tri-Service General Hospital

2. Fu-Jen Catholic University

3. National Defense Medical Center

Abstract

Abstract Background Proton pump inhibitors (PPIs) are common and widely used for gastrointestinal-related disorders. Lansoprazole is one of PPIs with potential benefits of anti-inflammation, reduced oxidative stress, and anti-diabetes. The aims of this study are to determine whether lansoprazole imparts differential risk of type 2 diabetes as compared with other PPIs. Methods A population-based retrospective cohort study was conducted using the National Health Insurance Research Database in Taiwan. Patients who received lansoprazole more than 90 days and without records of use of other PPIs between January 1, 2000 and December 31, 2005 (the exposure period) were considered as the exposed cohort (n = 1,668). In comparison, patients who received other PPIs more than 90 days and without use of lansoprazole in the exposure period were treated as the unexposed cohort (n = 3,336).The primary outcome was the new-onset of type 2 diabetes mellitus (T2DM). The association between lansoprazole use and the risk of T2DM was determined by hazard ratios (HRs) and 95% confidence intervals (CIs) derived from multivariable Cox proportional hazards models. Results The lansoprazole cohort showed a significantly reduced risk of T2DM with an adjusted HR of 0.65 (95% CI, 0.56–0.76). Interestingly, the inverse association between use of lansoprazole and risk of T2DM was observed in both men and women and in various age groups. Conclusion Our findings suggest that lansoprazole was associated with a reduced risk of T2DM compared with other PPIs. Further studies are needed to determine the clinical implications of the present study.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3